Prediction of heart failure in patients with type 2 diabetes mellitus-A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 108, Issue 1, 2015, Pages 55-66

  Wang, Ying ^a   Negishi, Tomoko ^a   Negishi, Kazuaki ^a   Marwick, Thomas H ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Heart failure; Predictor; Risk factors; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE DURATION; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; COMPLICATION; HEALTH; INCIDENCE; META ANALYSIS; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HEART FAILURE; HUMANS; INCIDENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84926204934     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.01.011     Document Type: Article

References (51)

1. Ambrosy A.P., Fonarow G.C., Butler J., et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014, 63:1123-1133.
2. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
3. Nichols G.A., Koro C.E., Gullion C.M., Ephross S.A., Brown J.B. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005, 21:51-57.
4. Barzilay J., Kronmal R. Are fasting glucose levels a risk factor for heart failure in older adults with diabetes?. Cardiol Rev 2005, 22. 20-22 + 25.
5. Velavan P., Khan N.K., Goode K., et al. Predictors of short term mortality in heart failure-insights from the Euro Heart Failure survey. Int J Cardiol 2010, 138:63-69.
6. Nichols G.A., Hillier T.A., Erbey J.R., Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001, 24:1614-1619.
7. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
8. Bell D.S.H. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433-2441.
9. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
10. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
11. Collaboration T.C. Cochrane handbook for systematic reviews of interventions 5.1.0 2011, Available from 〈www.cochrane.org/training/cochrane-handbook〉.
12. Bowden J., Tierney J.F., Copas A.J., Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol 2011, 11:41.
13. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
14. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
15. Marwick T.H. Diabetic heart disease. Heart 2006, 92:296-300.
16. Kiencke S., Handschin R., von Dahlen R., et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010, 12:951-957.
17. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
18. Abhayaratna W.P., Marwick T.H., Smith W.T., Becker N.G. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006, 92:1259-1264.
19. Dawson A., Morris A.D., Struthers A.D. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005, 48:1971-1979.
20. Fang Z.Y., Schull-Meade R., Leano R., Mottram P.M., Prins J.B., Marwick T.H. Screening for heart disease in diabetic subjects. Am Heart J 2005, 149:349-354.
21. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007, 357:28-38.
22. Toprani A., Fonseca V. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab 2011, 13:276-280.
23. Granberry M.C., Hawkins J.B., Franks A.M. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. Am J Health Syst Pharm 2007, 64:931-936. (AJHP: official journal of the American Society of Health-System Pharmacists).
24. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668-2673.
25. Yang X., Ma R.C., So W.Y., et al. Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 diabetes mellitus. Cardiovasc Diabetol 2008, 7:9.
26. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
27. Adler A.I., Stratton I.M., Neil H.A.W., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000, 321:412-419.
28. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
29. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., Parker M.M. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005, 22:986-993. (a journal of the British Diabetic Association).
30. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
31. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-2989.
32. Vaur L., Gueret P., Lievre M., Chabaud S., Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria of proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 2003, 26:855-860.
33. Rajagopalan R., Rosenson R.S., Fernandes A.W., Khan M., Murray F.T. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004, 26:1400-1410.
34. Maru S., Koch G.G., Stender M., et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005, 28:20-26.
35. Filion K.B., Joseph L., Boivin J.F., Suissa S., Brophy J.M. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2011, 20:785-796.
36. Banerjee D., Biggs M.L., Mercer L., et al. Insulin resistance and risk of incident heart failure: cardiovascular health study. Circ Heart Fail 2013, 6:364-370.
37. Held C., Gerstein H.C., Yusuf S., et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007, 115:1371-1375.
38. Erdmann E., Charbonnel B., Wilcox R.G., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
39. Erdmann E., Spanheimer R., Charbonnel B. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). J Diabetes 2010, 2:212-220.
40. Pfister R., Cairns R., Erdmann E., Schneider C.A., investigators P.R. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. Diabet Med 2011, 28:1206-1212.
41. Lipscombe L.L., Gomes T., Levesque L.E., Hux J.E., Juurlink D.N., Alter D.A. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
42. McAlister F.A., Eurich D.T., Majumdar S.R., Johnson J.A. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008, 10:703-708.
43. Leung A.A., Eurich D.T., Lamb D.A., et al. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail 2009, 15:152-157.
44. Cheung N., Wang J.J., Rogers S.L., et al. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 2008, 51:1573-1578.
45. Pazin-Filho A., Kottgen A., Bertoni A.G., et al. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2008, 51:2197-2204.
46. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010, 55:300-305.
47. de Simone G., Devereux R.B., Chinali M., et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens 2010, 28:353-360.
48. Komajda M., McMurray J.J.V., Beck-Nielsen H., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010, 31:824-831.
49. Lind M., Olsson M., Rosengren A., Svensson A.M., Bounias I., Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia 2012, 55:2946-2953.
50. Glogner S., Rosengren A., Olsson M., Gudbjornsdottir S., Svensson A.M., Lind M. The association between BMI and hospitalization for heart failure in 83 021 persons with Type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diabet Med 2013, 31:586-594. (a journal of the British Diabetic Association).
51. Ebong I.A., Goff D.C., Rodriguez C.J., Chen H., Sibley C.T., Bertoni A.G. Association of lipids with incident heart failure among adults with and without diabetes mellitus: multiethnic study of atherosclerosis. Circ Heart Fail 2013, 6:371-378.